NCT05620823

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 608 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.

Conditions

• Hidradenitis Suppurativa (HS)

Interventions

Type	Name	Description
DRUG	Povorcitinib	Oral; Tablet
DRUG	Placebo	Oral; Tablet

Timeline

• Start date: 2022-12-19
• Primary completion: 2025-02-03
• Completion: 2025-12-23
• First posted: 2022-11-17
• Last updated: 2026-02-10

Locations

104 sites across 12 countries: United States, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Japan, Netherlands, Poland, Spain

Regulatory

• FDA-regulated drug study